Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Brian I. Rini, MD1; Javid J. Moslehi, MD2,3; Marc Bonaca, MD, MPH4; Manuela Schmidinger, MD5; Laurence Albiges, MD, PhD6; Toni K. Choueiri, MD7; Robert J. Motzer, MD8; Michael B. Atkins, MD9; John Haanen, MD, PhD10; Mariangela Mariani, PhD11; Jing Wang, PhD12; Subramanian Hariharan, MD13; and James Larkin, MD, PhD14

abstract

PURPOSE Both immune checkpoint inhibitors (ICIs) and vascular endothelial growth factor receptor (VEGFR) inhibitors are approved for advanced renal cell carcinoma treatment and can cause cardiovascular events (CVs); thus, combination therapy could lead to major adverse CV events (MACE). Cardiac serum biomarker assessment and imaging, including left ventricular ejection fraction (LVEF) monitoring, can be used to evaluate MACE.

METHODS To our knowledge, the JAVELIN Renal 101 trial, assessing avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma, is the first randomized study of ICI plus VEGFR inhibitor treatment to include prospective serial cardiac monitoring of LVEF and serum cardiac biomarkers.

RESULTS MACE (defined as grade ≥ 3 CV AEs) occurred in 31 patients (7.1%) in the combination arm and 17 patients (3.9%) in the sunitinib arm. Patients in the combination arm who had high baseline troponin T values were at higher risk of MACE versus patients with low values (MACE in 6/35 vs 7/135, respectively; relative risk, 3.31; 95% CI, 1.19 to 9.22). This association was not observed in patients treated with sunitinib. Other CV baseline risk factors and serum cardiac biomarkers were not significantly predictive for MACE, although a trend toward an association with dyslipidemia was seen in the combination arm. No clinical value of on-treatment routine monitoring of LVEF in relation to MACE was observed. Although LVEF decline was significantly more frequent in the combination arm, most patients recovered, and decline was not associated with other significant cardiac events or symptoms.

CONCLUSION Patients with high baseline troponin T levels receiving ICI and VEGFR combinations may need to be monitored more closely for MACE. Routine monitoring of LVEF in asymptomatic patients is not recommended.

J Clin Oncol 40:1929-1938. © 2022 by American Society of Clinical Oncology

INTRODUCTION Combination therapy with immune checkpoint inhibitors (ICIs; anti–programmed death ligand 1 or anti–programmed death 1) and vascular endothelial growth factor (VEGF) pathway inhibitors is an effective treatment for several tumor types, including advanced renal cell carcinoma (aRCC).

Cardiovascular (CV) adverse events (AEs), including hypertension, cardiomyopathy, cardiac failure, and thromboembolic events, are a well-characterized occurrence with VEGF receptor (VEGFR) inhibitor monotherapy. ICIs can cause inflammatory CV AEs, including myocarditis, pericarditis, vasculitis, and arrhythmias. Although ICI-related myocarditis occurs in only approximately 1% of ICI-treated patients, it has a high fatality rate (46%) and almost 80% of events occur within six weeks of treatment initiation, highlighting a need for early detection. ICI combination therapy involving an anticytotoxic T-cell lymphocyte-4 antibody and an anti–programmed death 1/programmed death ligand 1 antibody is associated with a higher risk of myocarditis compared with monotherapy. Whether the risk of CV AEs is increased when ICIs are combined with VEGFR inhibitors is unknown. The role of serum cardiac biomarkers in patients receiving potentially cardiotoxic anticancer treatments, including ICIs, has been explored.

However, the impact of comorbidities, complete clinical features and characteristics, timing, and outcomes of immune-mediated CV AEs remain unclear.

In the JAVELIN Renal 101 phase III trial, avelumab plus axitinib significantly improved progression-free survival and the objective response rate versus...
sunitinib in previously untreated patients with aRCC. Unlike other phase III trials of ICI plus VEGFR inhibitor treatment, left ventricular ejection fraction (LVEF) and serum cardiac biomarkers were assessed prospectively. Here, we analyzed the incidence of major adverse CV events (MACE) in patients with aRCC receiving avelumab plus axitinib versus sunitinib in this trial, including the association between MACE and changes in LVEF or baseline levels of serum cardiac biomarkers.

METHODS

Study Design and Participants

The design of the JAVELIN Renal 101 trial has been reported in detail previously. Patients with aRCC were randomly assigned to receive avelumab (10 mg/kg) intravenously every 2 weeks plus axitinib (5 mg) orally twice daily or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). Random assignment was stratified according to Eastern Cooperative Oncology Group performance status (0 v 1) and geographic region (United States v Canada and Western Europe v the rest of the world). Inclusion and exclusion criteria have been reported previously. CV exclusion criteria included LVEF below the lower limit of normal (LLN) for the institution as assessed by either multigated acquisition (MUGA) scan or echocardiogram (ECHO). Full CV exclusion criteria are provided in the Data Supplement (online only).

An external data monitoring committee reviewed efficacy and safety. An independent cardiac events adjudication committee (CAC) reviewed CV AEs to confirm the diagnosis and relationship to study treatment (detailed in the Data Supplement). Schedules for MUGA scan or ECHO assessments and cardiac biomarker investigation are provided in the Data Supplement. Grade $\geq 3$ CV AEs (MACE), including myocarditis, LVEF change from baseline, and cardiac serum biomarker analysis at baseline and the first 16 weeks on treatment, were assessed as AEs of specific interest.

This trial was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines defined by the International Council for Harmonisation. All patients provided written, informed consent before enrollment. The Protocol (online only) was approved by the institutional review board or independent ethics committee at each participating center.

MACE and Baseline CV Risk Factors

MACE were defined according to NCI CTCAE version 4.3 and, consistent with US Food and Drug Administration guidance, included grade $\geq 3$ CV AEs of cardiac deaths, fatal stroke, nonfatal myocardial infarction, nonfatal congestive heart failure, nonfatal myocarditis, nonfatal arrhythmia, and nonfatal stroke. Myocarditis was diagnosed by investigators on the basis of new onset of cardiac signs or symptoms, new laboratory cardiac biomarker elevations, and cardiac imaging abnormalities suggestive of myocarditis. Suspected myocarditis events were reviewed by CAC and categorized as definite, probable, and possible per a consensus statement (Data Supplement). The relative risk of MACE was correlated with a prespecified list of baseline CV risk factors, which included age, sex, smoking status, body mass index, and medical history of hypertension, dyslipidemia, diabetes mellitus, and CNS vascular conditions.

LVEF

LVEF was assessed at baseline and day 1 of every two cycles using either MUGA scan or ECHO, per local site practice/preference. LVEF decline was defined as a $\geq 10$-point reduction from baseline to a value below the LLN.

Serum Cardiac Biomarkers

After consultation with the US Food and Drug Administration, serum cardiac biomarker monitoring in the first 16 weeks of treatment was added to the protocol while the study was ongoing to assess whether routine monitoring would improve early detection of myocarditis. Cardiac biomarkers (troponin I or T), B-type natriuretic peptide
TABLE 1. Patient Demographics at Baseline

| Characteristic                        | Avelumab Plus (n = 442) | Sunitinib (n = 444) |
|--------------------------------------|-------------------------|---------------------|
| Age, years, median (range)           | 62.0 (29.0-83.0)        | 61.0 (27.0-88.0)    |
| Sex, No. (%)                         |                         |                     |
| Male                                 | 316 (71.5)              | 344 (77.5)          |
| Female                               | 126 (28.5)              | 100 (22.5)          |
| Geographic region, No. (%)           |                         |                     |
| United States                        | 128 (29.0)              | 130 (29.3)          |
| Canada and Western Europe            | 128 (29.0)              | 128 (28.8)          |
| Rest of the world                    | 186 (42.1)              | 186 (41.9)          |
| Smoking history, No. (%)             |                         |                     |
| Never                                | 220 (49.8)              | 213 (48.0)          |
| Current                              | 43 (9.7)                | 49 (11.0)           |
| Former                               | 176 (39.8)              | 181 (40.8)          |
| Not reported                         | 3 (0.7)                 | 1 (0.2)             |
| BMI, kg/m², median (range)           | 27.45 (15.5-52.6)       | 27.36 (15.5-53.2)   |
| Select medical history, ongoing, No. (%) |                     |                     |
| Hypertension                         | 269 (60.9)              | 242 (54.5)          |
| Dyslipidemia                         | 19 (4.3)                | 10 (2.3)            |
| Diabetes mellitus                    | 42 (9.5)                | 34 (7.7)            |
| CNS vascular conditions              | 14 (3.2)                | 7 (1.6)             |
| Baseline cardiac biomarker levels, No. (%) |                 |                     |
| Troponin T                           |                         |                     |
| Low                                  | 0                       | 1 (0.5)             |
| Normal                               | 129 (79.6)              | 149 (80.1)          |
| High                                 | 33 (20.4)               | 36 (19.4)           |
| Troponin I                           |                         |                     |
| Low                                  | 9 (3.5)                 | 15 (5.6)            |
| Normal                               | 173 (82.8)              | 162 (87.1)          |
| High                                 | 4 (1.9)                 | 2 (1.1)             |
| BNP                                  |                         |                     |
| Low                                  | 0                       | 0                   |
| Normal                               | 152 (89.9)              | 116 (83.5)          |
| High                                 | 17 (10.1)               | 23 (16.5)           |
| NT-proBNP                            |                         |                     |
| Low                                  | 0                       | 0                   |
| Normal                               | 83 (63.4)               | 116 (69.0)          |
| High                                 | 47 (35.9)               | 51 (30.4)           |
| CK-MB                                |                         |                     |
| Low                                  | 5 (1.9)                 | 5 (1.9)             |
| Normal                               | 244 (94.6)              | 246 (92.5)          |
| High                                 | 9 (3.5)                 | 15 (5.6)            |

Abbreviations: BMI, body mass index; BNP, B-type natriuretic peptide; CK-MB, creatine kinase MB; NT-proBNP, N-terminal proB-type natriuretic peptide.

*The denominator used to calculate percentages for baseline cardiac biomarker levels (shown in each cell) is the number of patients with a baseline assessment and ≥ 1 postbaseline assessment for each parameter in each treatment arm. Low = below lower limit of normal range; normal = within the normal range; high = above the upper limit of normal range.

[BNP], N-terminal proBNP [NT-proBNP], and creatine kinase MB [CK-MB]) were measured at baseline on cycles 1, 2, and 3, on days 1, 15, and 29 of all three cycles, and when clinically indicated (Data Supplement). Cardiac biomarker data were assessed locally, and sites could monitor either troponin T or troponin I and BNP or NT-proBNP on the basis of site practice/preference. Low or high levels of biomarkers were defined as those below or above the investigator-defined LLN or upper limit of normal ranges, respectively. Normal levels of biomarkers were those within the normal range.

**Statistical Analysis**

The LVEF percentage was summarized using descriptive statistics of actual values and changes from baseline for each visit over time, and was summarized as frequency of patients with ≥ 10-point decline from baseline to a value below the LLN during treatment. The P value was calculated using the two-proportions Z-test. MACE were tabulated using descriptive statistics. MACE during the on-treatment period and with onset on or after LVEF decline were summarized. Cardiac biomarkers were summarized descriptively. Shift summaries of cardiac biomarker test results by baseline and worst on-treatment assessment were provided. Associations between baseline risk factors or cardiac biomarkers with MACE were described using relative risk and 95% CIs. Risk difference for MACE between study arms was computed. CIs were based on the unconditional exact method by Santner and Snell and were not adjusted for multiplicity, and the P value was calculated using asymptotic chi-square distribution.

**RESULTS**

**Baseline Demographics**

Between March 29, 2016, and December 19, 2017, 886 patients were assigned to avelumab plus axitinib (n = 442) or sunitinib (n = 444) arms; 873 patients received study treatment (434 and 439, respectively) and were evaluated for safety. At the data cutoff (June 20, 2018 [first interim analysis]; minimum follow-up of 6 months in all patients), median exposure to avelumab, axitinib, and sunitinib was 37.2 weeks (range, 0.1-108.3 weeks), 39.2 weeks (range, 0.1-108.3 weeks), and 31.7 weeks (range, 0.9-99.9 weeks), respectively. Approximately 60% of patients in each arm had a history of hypertension; other cardiac risk factors were not prevalent (Table 1).

**MACE**

MACE were reported in 31 patients (7.1%) in the avelumab plus axitinib arm and 17 patients (3.9%) in the sunitinib arm (Table 2). After adjusting for exposure to study treatment, the difference between arms was smaller than in the comparison of nonadjusted data (Data Supplement). Median time to first onset of MACE was 7.7 weeks (range, 0.1-73.3 weeks) in the combination arm and 17.6 weeks (range, 2.0-44.0 weeks) in the sunitinib arm (Data Supplement). Six patients (1.4%) in
The avelumab plus axitinib arm and one patient (0.2%) in the sunitinib arm had cardiac death; one patient in each treatment arm had a fatal stroke. More cardiac AEs occurred with avelumab plus axitinib and more nonfatal CNS vascular events occurred with sunitinib.

The difference in MACE rates between study arms could not be attributed to higher hypertension rates with avelumab plus axitinib (52.1%) versus sunitinib (39.0%) because MACE rates were similar in patients with or without hypertension (7.5% vs 6.8%, respectively; Data Supplement). Within the avelumab plus axitinib arm, most patients with MACE had one or two CV risk factors at baseline (28/31 [90.3%]). No significant correlation was observed between MACE and the baseline risk factors evaluated, except for a trend toward an association with dyslipidemia in the avelumab plus axitinib arm (Table 3).

Seven cases of myocarditis were reported (Data Supplement). Two events in the avelumab plus axitinib arm were assessed as definite myocarditis by the CAC (one fatal). Five events did not meet the criteria for definite myocarditis; two probable and two possible with avelumab plus axitinib, and one possible with sunitinib. The first case of definite myocarditis was a 55-year-old man who experienced a nonfatal event with onset after a single dose of avelumab with symptoms of cardiac failure; troponin levels were normal. The cardiac magnetic resonance imaging was consistent with myocarditis.

### Table 2. Summary of MACE During the On-Treatment Period (safety analysis set)

| MACE                                      | Avelumab Plus Axitinib (n = 434) | Sunitinib (n = 439) | Avelumab Plus Axitinib vs Sunitinib |
|--------------------------------------------|----------------------------------|--------------------|----------------------------------|
| MACE, total                                | 31 (7.1)                         | 17 (3.9)           | 0.033 –0.034 to 0.099            |
| Cardiac deaths                             | 6 (1.4)                          | 1 (0.2)            | 0.012 –0.055 to 0.078            |
| Cardiopulmonary failure                    | 0 (0)                            | 1 (0.2)            | —                                |
| Death                                      | 4 (0.9)                          | 0 (0)              | —                                |
| Myocarditis                                | 1 (0.2)                          | 0 (0)              | —                                |
| Sudden death                               | 1 (0.2)                          | 0 (0)              | —                                |
| Fatal stroke                               | 1 (0.2)                          | 1 (0.2)            | 0.000 –0.066 to 0.066            |
| Cerebrovascular accident                   | 1 (0.2)                          | 1 (0.2)            | —                                |
| Nonfatal arrhythmia                        | 4 (0.9)                          | 1 (0.2)            | 0.007 –0.060 to 0.073            |
| Atrial fibrillation                        | 4 (0.9)                          | 0 (0)              | —                                |
| Electrocardiogram QT prolonged             | 0 (0)                            | 1 (0.2)            | —                                |
| Nonfatal congestive heart failure          | 7 (1.6)                          | 3 (0.7)            | 0.009 –0.057 to 0.076            |
| Cardiac failure                            | 1 (0.2)                          | 0 (0)              | —                                |
| Ejection fraction decreased                | 6 (1.4)                          | 3 (0.7)            | —                                |
| Nonfatal myocardial infarction             | 9 (2.1)                          | 3 (0.7)            | 0.014 –0.053 to 0.080            |
| Acute coronary syndrome                    | 2 (0.5)                          | 0 (0)              | —                                |
| Acute myocardial infarction                | 3 (0.7)                          | 0 (0)              | —                                |
| Angina pectoris                            | 0 (0)                            | 2 (0.5)            | —                                |
| Coronary artery disease                    | 0 (0)                            | 1 (0.2)            | —                                |
| Coronary artery occlusion                  | 1 (0.2)                          | 0 (0)              | —                                |
| Myocardial ischemia                        | 0 (0)                            | 1 (0.2)            | —                                |
| Troponin I increased                       | 1 (0.2)                          | 0 (0)              | —                                |
| Troponin T increased                       | 1 (0.2)                          | 0 (0)              | —                                |
| Nonfatal myocarditis                       | 1 (0.2)                          | 0 (0)              | 0.002 –0.064 to 0.069            |
| Myocarditis                                | 1 (0.2)                          | 0 (0)              | —                                |
| Nonfatal stroke                            | 3 (0.7)                          | 8 (1.8)            | -0.011 –0.078 to 0.055           |
| Brain hypoxia                              | 0 (0)                            | 1 (0.2)            | —                                |
| Cerebellar hemorrhage                      | 0 (0)                            | 1 (0.2)            | —                                |
| Cerebrovascular accident                   | 2 (0.5)                          | 2 (0.5)            | —                                |

**Note.** The denominator to calculate percentages is the number of patients in the safety analysis set within each treatment group. CIs for the risk difference were based on the unconditional exact method by Santner and Snell and were not adjusted for multiplicity.

Abbreviations: MACE, major adverse cardiovascular events; QT, interval from beginning of QRS complex to end of T wave.
with myocarditis but the cardiac biopsy was negative. The patient was treated with high-dose steroids but relapsed (both clinically and by imaging) during steroid tapering. The event resolved after a second cycle of high-dose steroids with prolonged tapering. The second case of definite myocarditis was an 80-year-old woman who experienced myocarditis with onset after two doses of avelumab. The patient developed high troponin levels. Although initially asymptomatic, the clinical presentation rapidly evolved with several episodes of ventricular arrhythmia. Cardiac magnetic resonance imaging was not performed. The patient was treated with high-dose steroids from day 9 after clinical onset. The myocarditis was fatal; no autopsy was performed.

LVEF

The maximum LVEF decrease from baseline per patient during treatment and LVEF changes from baseline during the treatment period are shown (Fig 1). In the avelumab plus axitinib and sunitinib arms, 37 patients (8.5%) and seven patients (1.6%), respectively (P < .0001), experienced an LVEF decline (as defined in the Methods section) during treatment (Table 4). Decline in LVEF was noted as early as week 6 of treatment and nearly 80% occurred within the first year on treatment (Data Supplement). The median time to onset of LVEF decline was longer with avelumab plus axitinib versus sunitinib (18.1 v 7.6 weeks, respectively). At week 14, among the 37 patients who had LVEF decline with avelumab plus axitinib, 22 (59.5%) had recovered to an LVEF value above the LLN and 15 (40.5%) had not recovered. No correlation between LVEF decline and MACE was observed in either arm. Among patients who had an LVEF decline with avelumab plus axitinib, 22 (59.5%) had recovered to an LVEF value above the LLN and 15 (40.5%) had not recovered. No correlation between LVEF decline and MACE was observed in either arm. Among patients who had an LVEF decline with avelumab plus axitinib, one had cardiac death and one discontinued avelumab only (Data Supplement). No patient in the sunitinib arm had MACE following an LVEF decline. Asymptomatic LVEF decrease was not an indication for treatment modification per study protocol.

Serum Cardiac Biomarker Analysis

Baseline levels of serum cardiac biomarkers and changes from baseline are shown in Table 1 and the Data

---

**TABLE 3.** Relative Risk of MACE by Baseline Characteristics (safety analysis set)

| Characteristic                        | Avelumab Plus Axitinib (n = 434) | Sunitinib (n = 439) |
|---------------------------------------|-----------------------------------|--------------------|
|                                       | MACE, No.  | No MACE, No. | Relative Risk of MACE (95% CI) | MACE, No.  | No MACE, No. | Relative Risk of MACE (95% CI) |
| Age, years                            |           |              |                                 |           |              |                                 |
| ≥ 75                                  | 4         | 29           | 1.80 (0.67 to 4.84)             | 0         | 40           | 0                                 |
| < 75                                  | 27        | 374          | 0.85 (0.41 to 1.75)             | 12        | 327          | 0.71 (0.26 to 1.96)               |
| Sex                                   |           |              |                                 |           |              |                                 |
| Male                                  | 21        | 288          | 0.85 (0.41 to 1.75)             | 12        | 327          | 0.71 (0.26 to 1.96)               |
| Female                                | 10        | 115          | 0.85 (0.41 to 1.75)             | 5         | 95           | 0.85 (0.41 to 1.75)               |
| Smoking status                        |           |              |                                 |           |              |                                 |
| Smoker                                | 13        | 200          | 0.79 (0.39 to 1.58)             | 9         | 220          | 1.03 (0.40 to 2.61)               |
| Nonsmoker                             | 17        | 202          | 0.79 (0.39 to 1.58)             | 8         | 201          | 1.03 (0.40 to 2.61)               |
| BMI                                   |           |              |                                 |           |              |                                 |
| ≥ 30                                  | 11        | 116          | 1.31 (0.65 to 2.66)             | 6         | 133          | 1.27 (0.47 to 3.43)               |
| < 30                                  | 20        | 283          | 1.31 (0.65 to 2.66)             | 10        | 285          | 1.31 (0.65 to 2.66)               |
| Blood pressure status                 |           |              |                                 |           |              |                                 |
| Hypertension                          | 24        | 250          | 2.00 (0.88 to 4.54)             | 13        | 240          | 2.39 (0.79 to 7.21)               |
| No hypertension                       | 7         | 153          | 2.00 (0.88 to 4.54)             | 4         | 182          | 2.00 (0.88 to 4.54)               |
| Lipid status                          |           |              |                                 |           |              |                                 |
| Dyslipidemia                          | 10        | 72           | 2.04 (1.00 to 4.17)             | 3         | 66           | 1.15 (0.34 to 3.89)               |
| No dyslipidemia                       | 21        | 331          | 2.04 (1.00 to 4.17)             | 14        | 356          | 2.04 (1.00 to 4.17)               |
| Blood glucose status                  |           |              |                                 |           |              |                                 |
| Diabetes                              | 4         | 76           | 0.66 (0.24 to 1.82)             | 5         | 72           | 1.96 (0.71 to 5.40)               |
| No diabetes                           | 27        | 327          | 0.66 (0.24 to 1.82)             | 12        | 350          | 0.66 (0.24 to 1.82)               |
| CNS vascular/cardiac condition        |           |              |                                 |           |              |                                 |
| Present                               | 7         | 58           | 1.66 (0.74 to 3.68)             | 4         | 49           | 2.24 (0.76 to 6.62)               |
| Not present                           | 24        | 345          | 1.66 (0.74 to 3.68)             | 13        | 373          | 1.66 (0.74 to 3.68)               |

Abbreviations: BMI, body mass index; MACE, major adverse cardiovascular events.
Supplement, respectively. In both arms, similar proportions of patients had high (above the upper limit of normal range) troponin T levels at baseline (20.4% with avelumab plus axitinib vs 19.4% with sunitinib). In the sunitinib arm versus the avelumab plus axitinib arm, a higher proportion had normal baseline troponin T and at least one high troponin T value on treatment (22.0% vs 13.0%, respectively). Baseline troponin I levels were high in 1.9% in the avelumab plus axitinib arm versus 1.1% in the sunitinib arm. In both arms, a similar proportion had low or normal baseline troponin I and developed at least one high value on treatment (8.6% with avelumab plus axitinib vs 8.1% with sunitinib). The median time to onset of high troponin levels (combined troponin I and T analysis) was 4.1 weeks in both arms.

In the avelumab plus axitinib arm, a higher proportion of patients with high baseline troponin T developed MACE versus patients without high baseline troponin T (6/35 [17.1%] vs 7/135 [5.2%]; relative risk, 3.31; 95% CI, 1.19 to 9.22; Table 5). This difference was statistically significant at the 0.05 level (P = .022). In the sunitinib arm, occurrence of MACE was not significantly different between patients with or without high baseline troponin T levels. Occurrence of MACE did not correlate with baseline levels of other cardiac biomarkers in either arm (Table 5). Baseline cardiac biomarkers were not predictive of myocarditis, potentially because of its rarity in the study population. Of the seven patients with myocarditis, troponin levels were measured at baseline in six patients (troponin T in three patients and troponin I in four patients), and troponin T was high in one patient.

Of 65 patients in the avelumab plus axitinib or sunitinib arm who had a normal baseline troponin T and at least one high troponin T value on treatment (n = 21 and n = 41, respectively), one patient in each arm developed MACE (myocarditis and nonfatal stroke, respectively). Of 31 patients who had a normal baseline troponin I and at least one high troponin I value while on treatment (avelumab plus axitinib, n = 16; sunitinib, n = 15), MACE occurred in four patients.

FIG 1. Waterfall plot of maximum decrease in LVEF from baseline during therapy and change from baseline in LVEF during the on-treatment period (patient with LVEF% decrease ≥ 10 points from baseline) with (A, C) avelumab plus axitinib or (B, D) sunitinib. LLN, lower limit of normal; LVEF, left ventricular ejection fraction; MACE, major adverse cardiovascular events.
TABLE 4. Summary of Patients With LVEF% Decrease of at Least 10 Points From Baseline to a Postbaseline Value Below the LLN During On-Treatment Period—Safety Analysis Set

| Characteristic | Avelumab Plus Axitinib (n = 434) | Sunitinib (n = 439) |
|----------------|----------------------------------|--------------------|
| Patients with LVEF% ≥ 10-point decrease from baseline to a postbaseline value < LLN, No. (%)a | 37 (8.5) | 7 (1.6) |
| Time to onset of LVEF% ≥ 10-point decrease from baseline to postbaseline value < LLN, median, weeksb | 18.1 | 7.6 |

Recovery

| Recovery | Avelumab Plus Axitinib (n = 434) | Sunitinib (n = 439) |
|----------|----------------------------------|--------------------|
| Time to LVEF recovery, median, weeks | 12.1 | 12.2 |
| Recovered, No. (%)c | 22 (59.5) | 4 (57.1) |
| Ongoing, No. (%)d | 15 (40.5) | 3 (42.9) |

Abbreviations: LLN, lower limit of normal; LVEF, left ventricular ejection fraction.

aThe denominator to calculate percentages is the number of patients in the safety analysis set within each treatment group.
bTime to first onset of LVEF% decrease of at least 10 points from baseline to a postbaseline value below the LLN (weeks) = (earliest onset date of LVEF% ≥ 10-point decrease from baseline to postbaseline value < LLN during the on-treatment period – date of first dose of study treatment ÷ 1)/7.
cThe denominator to calculate percentages is the number of patients in the safety analysis set with LVEF% decrease of at least 10 points from baseline to a postbaseline value below the LLN.
dLVEF recovery is defined as LVEF% decrease that has recovered to a value of at least the LLN after an at least 10-point decrease from baseline to a postbaseline value below the LLN during the on-treatment period.

(avelumab plus axitinib: nonfetal congestive heart failure [n = 2], nonfetal myocardial infarction; sunitinib: fetal stroke).

**DISCUSSION**

Both ICIs and VEGFR inhibitors have been associated with CV AEs of different types, creating a theoretical potential for an increased incidence of MACE with combination treatment. To our knowledge, JAVELIN Renal 101 is the first trial where LVEF and serum cardiac biomarkers were assessed prospectively in patients treated with an ICI plus VEGFR inhibitor. Serial cardiac imaging (ECHO or MUGA to measure LVEF changes) and measurement of serum biomarker (troponin T and I, BNP, NT-proBNP, and CK-MB) levels were evaluated per institutional standard practice, and their predictive correlation with MACE was assessed. Of particular interest were troponin T and I, which are biomarkers of myocardial inflammation and damage from myocarditis.20,21 One study found that troponin T was elevated in 94% of ICI-associated myocarditis cases, and the degree of elevation was a predictor of MACE.13

Although MACE were more frequent with avelumab plus axitinib versus sunitinib, the difference was not statistically significant, and the difference between arms was reduced in exposure-adjusted analyses. Although most patients with MACE had at least one baseline CV risk factor, no statistically significant associations with MACE were observed, except for a trend toward an association with dyslipidemia with avelumab plus axitinib. One patient in each treatment arm had a fatal stroke, and six patients (1.4%) and one patient (0.2%) had cardiac death in the avelumab plus axitinib and sunitinib arms, respectively.

Consistent with studies of ICI monotherapy, definite myocarditis with avelumab plus axitinib was rare (< 1%).10,14,22 Routine monitoring of baseline serum cardiac biomarkers in asymptomatic patients was not found to be useful for early identification of myocarditis in this study. For patients with suspected immune-related myocarditis receiving combination ICI/VEGFR inhibitor therapy, aggressive management including high-dose prednisolone (1-2 mg/kg) has been recommended.23 LVEF decline was more frequent with avelumab plus axitinib versus sunitinib. The timing of LVEF assessment (on day 1 of treatment cycles, ie, during daily axitinib treatment in the combination arm but after 2 weeks off treatment in the sunitinib arm) may explain the increased occurrence of LVEF decline in the avelumab plus axitinib arm; this limitation was also highlighted in the ASSURE cardiac substudy of sunitinib and sorafenib.24 In the combination arm, most patients with an LVEF decline recovered with or without dose modification of study drugs, and the decline was not associated with significant cardiac events or symptoms. On the basis of these findings, routine monitoring of LVEF in asymptomatic patients treated with an ICI plus VEGFR inhibitor or VEGFR inhibitor monotherapy is not recommended.

The role of serum cardiac biomarkers in assessing patients before ICI treatment is unknown. In this study, baseline levels of troponin T were high in approximately 20% of patients in both treatment arms. In the avelumab plus axitinib arm, MACE were more common in patients with high troponin T levels at baseline. Previous studies have reported that elevated troponin T levels are more likely in patients with renal impairment.25,26 In the JAVELIN Renal 101 trial, 80% of patients had undergone a prior nephrectomy,3 which might have influenced the observed correlation between MACE and a high baseline troponin T level in this analysis. We suggest that baseline assessment of troponin T levels may be considered when starting treatment with an ICI plus a VEGFR inhibitor, particularly in patients with CV risk factors. Patients with high troponin T levels should be monitored closely for cardiac symptoms during treatment, potentially including ECG monitoring, and a cardiologist should be involved in patient management from the outset of treatment. However, because of the small number of patients with MACE in our study, the predictive value of serum biomarkers other than troponin T cannot be ruled out. In addition, variability in the sensitivity of troponin T and I assays have been reported, which may
affect analyses of correlation with MACE.\textsuperscript{27,28} Larger studies are needed to confirm the findings in this study.

Our study has several potential limitations. Biomarker assays were not standardized between study sites, potentially causing variation in sensitivity limits.\textsuperscript{16} Additionally, clinicians were permitted to monitor the biomarkers that were convenient and feasible at each study site; thus, all biomarkers were not monitored at all study sites and some biomarkers had a small sample size. On-treatment electrocardiogram measurements were not reported in this study; this measurement was only performed at baseline, and serial monitoring was not required if there were no signs of arrhythmias at baseline. It was also not possible to separate cardiotoxicity associated with ICI versus VEGFR inhibitor treatment in the avelumab plus axitinib arm; hence, the drug causing MACE could not be distinguished. Finally, the study provided data only for avelumab plus axitinib treatment; similar prospective studies of other ICI-based combinations are needed to confirm findings and enable broader recommendations to be established.

In conclusion, the cardiac safety profile of avelumab plus axitinib did not show any new safety concerns compared with the known safety profiles seen in previous mono-therapy studies. Although MACE were more frequently observed with avelumab plus axitinib versus sunitinib, the overall incidence of MACE was low in both arms. Routine cardiac investigations in asymptomatic patients were not useful for early detection of CV AEs, including myocarditis. MACE were not associated with LVEF decline or with hypertension or most other baseline risk factors. However, high baseline troponin T levels were predictive of MACE with avelumab plus axitinib, suggesting that patients found to have high troponin T levels may require additional cardiac monitoring. Cardiac history should not exclude patients from receiving ICI plus VEGFR combination therapy.

### AFFILIATIONS

\textsuperscript{1}Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN

\textsuperscript{2}Section of Cardio-Oncology & Immunology, Division of Cardiology, Cardiovascular Research Institute, University of California San Francisco School of Medicine, San Francisco, CA

\textsuperscript{3}Vanderbilt University Medical Center, Nashville, TN

\textsuperscript{4}Colorado Prevention Center Clinical Research, Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO

\textsuperscript{5}Department of Urology and Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel, Vienna, Austria

\textsuperscript{6}Medical Oncology Department, Institut Gustave Roussy, Villejuif, France

\textsuperscript{7}Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA

\textsuperscript{8}Memorial Sloan Kettering Cancer Center, New York, NY

\textsuperscript{9}Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

\textsuperscript{10}Netherlands Cancer Institute, Amsterdam, the Netherlands

\textsuperscript{11}Oncology Research Unit, Pfizer srl, Milano, Italy

\textsuperscript{12}Statistics, Pfizer, Cambridge, MA

\textsuperscript{13}Oncology, Pfizer, New York, NY

\textsuperscript{14}Royal Marsden NHS Foundation Trust, London, United Kingdom

### TABLE 5. Relative Risk of MACE by Serum Cardiac Biomarker Levels at Baseline

| Cardiac Serum Biomarker | Avelumab Plus Axitinib (n = 434) | Sunitinib (n = 439) |
|------------------------|----------------------------------|---------------------|
|                        | MACE, No. | No MACE, No. | Relative Risk of MACE (95% CI) | MACE, No. | No MACE, No. | Relative Risk of MACE (95% CI) |
| Troponin T             |          |              |                               |          |              |                               |
| High                   | 6        | 29           | 3.31 (1.19 to 9.22)           | 2        | 39           | 0.89 (0.2 to 3.98)            |
| Not high               | 7        | 128          |                                | 9        | 156          |                                |
| Troponin I             |          |              |                               |          |              |                               |
| High                   | 0        | 4            | 0.89 (0.2 to 3.98)            | 0        | 2            | 0                              |
| Not high               | 15       | 206          |                                | 6        | 203          |                                |
| BNP                    |          |              |                               |          |              |                               |
| High                   | 2        | 15           | 2.04 (0.48 to 8.68)           | 0        | 25           | 0                              |
| Not high               | 9        | 147          |                                | 2        | 125          |                                |
| NT-proBNP              |          |              |                               |          |              |                               |
| High                   | 7        | 45           | 2.34 (0.78 to 7)              | 1        | 53           | 0.29 (0.04 to 2.28)           |
| Not high               | 5        | 82           |                                | 8        | 118          |                                |
| CK-MB                  |          |              |                               |          |              |                               |
| High                   | 2        | 8            | 2.68 (0.72 to 9.98)           | 0        | 16           | 0                              |
| Not high               | 19       | 236          |                                | 11       | 256          |                                |

Abbreviations: BNP, B-type natriuretic peptide; CK-MB, creatine kinase MB; MACE, major adverse cardiovascular events; NT-proBNP, N-terminal proBNP.
CORRESPONDING AUTHOR
Brian I. Rini, MD, Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN 37232; e-mail: brian.rini@vumc.org.

SUPPORT
This work was sponsored by Pfizer as part of an alliance between Pfizer and the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). The conduct of the trial at the Memorial Sloan Kettering Cancer Center was supported in part by Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748).

CLINICAL TRIAL INFORMATION
NCT02684006

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.21.01806.

DATA SHARING STATEMENT
Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual deidentified participant data. See https://www.pfizer.com/science/clinical-trials/trial-data-and-results for more information.

REFERENCES
1. Rini BI, Plimack ER, Stus V, et al: Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1116-1127, 2019
2. Rini BI, Powles T, Atkins MB, et al: Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet 393:2404-2415, 2019
3. Motzer RJ, Penkov K, Haenlen J, et al: Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 380:1103-1115, 2019
4. Makker V, Taylor MH, Aghajanian C, et al: Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer. J Clin Oncol 38:2981-2992, 2020
5. Choueiri TK, Motzer RJ, Rini BI, et al: Updated efficacy results from the JAVELIN renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030-1039, 2020
6. Finns RS, Qin S, Ikeda M, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894-1905, 2020
7. Moslehi JJ: Cardiovascular toxic effects of immunotherapies. N Engl J Med 375:1457-1467, 2016
8. Touyz RM, Herrmann SMS, Herrmann J: Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertens 12:409-425, 2018
9. Bair SM, Choueiri TK, Moslehi J: Cardiovascular complications associated with novel angiogenesis inhibitors: Emerging evidence and evolving perspectives. Trends Cardiovasc Med 23:104-113, 2013
10. Salem JE, Manouchehri A, Moey M, et al: Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study. Lancet Oncol 19:1579-1589, 2018
11. Hu JR, Florido R, Lipson EJ, et al: Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 115:854-868, 2019
12. Lutgens E, Seijkens TTP: Cancer patients receiving immune checkpoint inhibitor therapy are at an increased risk for atherosclerotic cardiovascular disease. J Immunother Cancer 6:e00300, 2020
13. Mahmood SS, Fadley MG, Cohen JV, et al: Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol 71:1755-1764, 2018
14. Moslehi JJ, Salem JE, Sosman JA, et al: Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391:933, 2018
15. Wang DY, Okoye GD, Neilan TG, et al: Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep 21:1921, 2017
16. Pudli R, Mueller C, Celutkien J, et al: Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail 22:1966-1983, 2020
17. Lee Chuy K, Okonnomou EK, Postow MA, et al: Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: The Memorial Sloan Kettering Cancer Center experience. Oncologist 24:e190-e197, 2019
18. Michel L, Mincu RI, Mrotzek SM, et al: Cardiac biomarkers for the detection of cardiotoxicity in childhood cancer-a meta-analysis. ESC Heart Fail 7:423-433, 2020
19. Bonaca MP, Olenchock BA, Salem JE, et al: Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation 140:80-91, 2019
20. Shah KS, Yang EH, Maisel AS, et al: The role of biomarkers in detection of cardio-toxicity. Curr Oncol Rep 19:42, 2017
21. Wallace KB, Hausner E, Herman E, et al: Serum troponins as biomarkers of drug-induced cardiac toxicity. Toxicol Pathol 32:106-121, 2004

AUTHOR CONTRIBUTIONS
Conception and design: Javid J. Moslehi, Manuela Schmidinger, Laurence Albige, Robert J. Motzer, Michael B. Atkins, Mariangela Mariani, Javid J. Moslehi, Manuela Schmidinger, Laurence Albiges, Robert J. Motzer, Michael B. Atkins, John Haanen, Mariangela Mariani
Provision of study materials or patients: Laurence Albiges, Toni K. Choueiri, Robert J. Motzer, Michael B. Atkins, John Haanen, Mariangela Mariani
Collection and assembly of data: Javid J. Moslehi, Manuela Schmidinger, Laurence Albiges, Robert J. Motzer, Michael B. Atkins, John Haanen, Mariangela Mariani
Data analysis and interpretation: Brian I. Rini, Marc Bonaca, Manuela Schmidinger, Laurence Albiges, Toni K. Choueiri, Robert J. Motzer, Michael B. Atkins, Mariangela Mariani, Jing Wang, Subramanian Hanirhan, James Larkin

Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT
The authors thank the patients and their families, investigators, coinvestigators, and the study teams at each of the participating centers. Medical writing support was provided by Graeme Hacking and Shilpa Lalchandani from ClinicalThinking, and funded by Pfizer and the healthcare business of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID: 10.13039/100009945). The authors also thank Camila Fowst from Pfizer for contributing to the analyses. Also supported by National Institutes of Health grants (R01HL141466, R01HL155990, and R01HL156021; J.J.M.) and Memorial Sloan Kettering Cancer Center Support Grant/Core Grant (P30 CA008748; R.J.M.).
22. Guo CW, Alexander M, Dib Y, et al: A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. Eur J Cancer 124:15-24, 2020
23. Grunwald V, Voss MH, Rini BI, et al: Axitinib plus immune checkpoint inhibitor: Evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. Br J Cancer 123:898-904, 2020
24. Haas NB, Manola J, Ky B, et al: Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases: Results from ASSURE, ECOG 2805. Clin Cancer Res 21:4048-4054, 2015
25. Dubin RF, Li Y, He J, et al: Predictors of high sensitivity cardiac troponin T in chronic kidney disease patients: A cross-sectional study in the chronic renal insufficiency cohort (CRIC). BMC Nephrol 14:229, 2013
26. Bargnoux AS, Kuster N, Patrier L, et al: Cardiovascular risk stratification in hemodialysis patients in the era of highly sensitive troponins: Should we choose between hs-troponin I and hs-troponin T? Clin Chem Lab Med 54:673-682, 2016
27. Apple FS, Collinson PO; IFCC Task Force on Clinical Applications of Cardiac Biomarkers: Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 58:54-61, 2012
28. Rubini Gimenez M, Twerenbold R, Reichlin T, et al: Direct comparison of high-sensitivity-cardiac troponin I vs. T for the early diagnosis of acute myocardial infarction. Eur Heart J 35:2303-2311, 2014
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/wc or ascopubs.org/loc/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Brian I. Rini
Leadership: MJH Life Sciences
Stock and Other Ownership Interests: PTC Therapeutics
Consulting or Advisory Role: Pfizer, Merck & Co (Kenilworth, NJ), Synthorx, Bristol Myers Squibb, AVEX, Surface Oncology, 3D Medicines, Corvus Pharmaceuticals, Aravive, Arrowhead Pharmaceuticals, Shionogi, Eisai, GlaxoSmithKline
Research Funding: Pfizer (Inst), Roche/Genentech (Inst), Bristol Myers Squibb (Inst), Merck & Co (Kenilworth, NJ) (Inst), AstraZeneca/MedImmune (Inst), Incyte (Inst), Arrowhead Pharmaceuticals (Inst), Taris (Inst), Seattle Genetics (Inst), Immunomedics (Inst), Surface Oncology (Inst), Dragonfly Therapeutics (Inst), Aravive (Inst), Exelixis (Inst)
Travel, Accommodations, Expenses: Pfizer, Bristol Myers Squibb, Merck & Co (Kenilworth, NJ)

Javid J. Mosleh
Consulting or Advisory Role: Arevate Therapeutics, AstraZeneca, Audentes Therapeutics, Pharmaceuticals, Boehringer, Bristol Myers Squibb, Cytokinetics, Deciphera, GlaxoSmithKline, Kurume Therapeutics, Mallinckrodt Pharmaceuticals, Myokardia, Myovant, Novartis, Pfizer, Pharmacies, ProteinCure, Takeda, Silverback Therapeutics, Star Therapeutics
Marc Bonaca
Research Funding: ARCA BioPharma (Inst), AstraZeneca/MedImmune (Inst), Bayer (Inst), Roche (Inst), CellResearch (Inst), EvryWell (Inst), Janssen (Inst), Novo Nordisk (Inst), Osiris Medical (Inst), Amgen (Inst), HDL Therapeutics (Inst)
Manuela Schmiding
Honoraria: Pfizer, Bristol Myers Squibb, Ipsen, Roche/Genentech, Merck & Co (Kenilworth, NJ), EISAI, EUSA Pharma, ALKERMES
Consulting or Advisory Role: Pfizer, Bristol Myers Squibb, Roche, Ipsen, Merck & Co (Kenilworth, NJ), EUSA Pharma, Eisai, Travel, Accommodations, Expenses: Bristol Myers Squibb, Roche, Ipsen

Laurence Albiges
Consulting or Advisory Role: Bristol Myers Squibb (Inst), Ipsen (Inst), Roche (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Merck & Co (Kenilworth, NJ) (Inst), AstraZeneca (Inst), Janssen (Inst), EISAI (Inst), Corvus Pharmaceuticals (Inst), Bellersphon Therapeutics (Inst)
Research Funding: Bristol Myers Squibb (Inst), Travel, Accommodations, Expenses: Bristol Myers Squibb, Merck & Co (Kenilworth, NJ)

Toni K. Choueiri
Employment: Dana Farber Cancer Hospital Leadership: Dana Farber Cancer Hospital, NCCN, KidneyCan, ASCO
Stock and Other Ownership Interests: Pionyr, Tempest Therapeutics
Honoraria: NCCN, UpToDate, Michael J. Hennessy Associates, ASCO, Harborside Press, Analysis Group, AstraZeneca, Alexion Pharmaceuticals, SanofiAventis, Bayer, Bristol Myers Squibb, Genentech/Roche, GlaxoSmithKline, Merck & Co (Kenilworth, NJ), Novartis, Peloton Therapeutics, Pfizer, Corvus Pharmaceuticals, Ipsen, Foundation Medicine, Eisai, PlatformQ Health, Clinical Care Options, Navinata Health, Kidney Cancer Association, Exelixis, Prometheus, Lpath, The New England Journal of Medicine, Lancel Oncology, Merck KGaA (Darmstadt, Germany), HERON, Lilly, Janssen Oncology, IQvia, Aveo, NCI Gastrointestinal Cancers Steering Committee
Consulting or Advisory Role: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck & Co (Kenilworth, NJ), Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Exelixis, Prometheus, alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, SanofiAventis, UpToDate, Peloton Therapeutics, NCCN, Michael J. Hennessy Associates, Analysis Group, Kidney Cancer Association, Clinical Care Options, PlatformQ Health, Navinata Health, Harborside Press, ASCO, The New England Journal of Medicine, Lancel Oncology, the healthcare business of Merck KGaA (Darmstadt, Germany), HERT, Lilly, ESMO, Other Relationship: Medical writing and editorial assistance support may have been funded by communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel

Robert J. Motzer
Consulting or Advisory Role: Novartis, Eisai, Exelixis, Merck & Co (Kenilworth, NJ), Genentech/Roche, Incyte, Lilly, Pfizer, AstraZeneca, the healthcare business of Merck KGaA (Darmstadt, Germany), Califera Biosciences, Aveo Research Funding: Pfizer (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Genentech/Roche (Inst), Exelixis (Inst), Merck & Co (Kenilworth, NJ) (Inst), Aveo (Inst)

Michael B. Atkins
Stock and Other Ownership Interests: Werewolf Pharma, Pyxis Consulting or Advisory Role: Genentech, Novartis, Bristol Myers Squibb, Merck & Co (Kenilworth, NJ), Exelixis, Eisai, Agenus, Arrowhead Pharmaceuticals, Werewolf Pharma, Surface Oncology, Iovance Biotherapeutics, Pyxis, Pneuma Respiratory, Leads BioLabs, Fathom Biotechnology, Aveo, Cota Healthcare, Neoleukin Therapeutics, Adagene, Ideca, Ellipses Pharma, AstraZeneca, PACT Pharma, Seattle Genetics, Pfizer, Scholar Rock, Asher Biotherapeutics, Califera Biosciences, Takeda, Sanofi, Simcha Therapeutics
Research Funding: Bristol Myers Squibb (Inst), John Haagen
Stock and Other Ownership Interests: Neogene Therapeutics Consulting or Advisory Role: Merck & Co (Kenilworth, NJ) (Inst), Pfizer (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Roche/Genentech (Inst), Ipsen (Inst), Achilles Therapeutics (Inst), Immunocore (Inst), Sanofi (Inst), Third Rock Ventures (Inst), Neogene Therapeutics, Molecular Partners (Inst), bioNTech (Inst), T-Knife (Inst), PokeAcel (Inst), Instil Bio (Inst), Iovance Biotherapeutics (Inst)
Research Funding: Merck & Co (Kenilworth, NJ) (Inst), Bristol Myers Squibb (Inst), Novartis (Inst), Neon Therapeutics (Inst), Amgen (Inst), BioNTech (Inst), Asher Biotherapeutics (Inst)

Mariangela Mariani
Stock and Other Ownership Interests: Pfizer

Jing Wang
Employment: Pfizer

Subramanian Hariharan
Employment: Pfizer

James Larkin
Honoraria: Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Novartis, Roche/Genentech, Incyte, Oncura, the healthcare business of Merck KGaA
Consulting or Advisory Role: Bristol Myers Squibb, GlaxoSmithKline, Pfizer, Novartis, Boston Biomedical, Incyte, iOnctura, ImmunoBiotherapeutics, Immunocore, YKT Corporation, Apple Tree Partners

Research Funding: Pfizer (Inst), Novartis (Inst), Merck & Co (Kenilworth, NJ) (Inst), Bristol Myers Squibb (Inst), Achilles Therapeutics (Inst), Roche (Inst), Nektar (Inst), Covance (Inst), Immunocore (Inst), AVEO (Inst), Pharmacyclics (Inst)

Travel, Accommodations, Expenses: Bristol Myers Squibb, Pfizer, Novartis, Roche/Gentech, AstraZeneca, Incyte, GlaxoSmithKline, Pierre Fabre, the healthcare business of Merck KGaA (Darmstadt, Germany), iOnctura, British Uro-Oncology Group (BUG), ESMO, National Cancer Research Institute (NCRI), EUSA Pharma, Syneos Health, Kidney Cancer Association, Bioevents, MedConcept, RV Mais

No other potential conflicts of interest were reported.